LEIDEN, NETHERLANDS--(MARKET WIRE)--Sep 25, 2007 -- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today stated that it wishes to emphasize that the discontinuation of Merck's HIV phase I and II studys, as announced on Friday September 21, is not related to the use of Crucell's PER.C6® technology. The company further added that it reiterates its guidance for 2007 at EUR 220 to 225 million operational cash break even.
